First patient treated in Phase I VXM01 glioblastoma trial
The first patient has been successfully treated in a Phase I clinical trial with Vaximm’s oral T-cell immunotherapy, VXM01, in glioblastoma.
Click on this link for more information.
top of page
bottom of page